Ariceum Therapeutics

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company, established in 2021, with a focus on developing innovative drugs for systemic targeted radiotherapy (STR). The company's lead product, 177 Lu-satoreotide tetraxetan (Satoreotide), is designed as a theranostic pair for the diagnosis and targeted radionuclide treatment of neuroendocrine cancers and aggressive tumors, addressing areas with limited treatment options and poor prognoses. Having acquired all rights to their lead product from Ipsen, Ariceum Therapeutics is headquartered in Berlin, Germany and has operations in Europe, North America, and Australia. The company recently secured a significant €22.75M Series A investment on 18 April 2023, with backing from prominent investors such as Earlybird, Andera Partner, and Pureos Bioventures. With a strong emphasis on biotechnology and healthcare, Ariceum Therapeutics aims to advance the diagnosis and precision treatment of challenging cancers, demonstrating potential for growth and impact in the health and wellness industry.